Dennie T. Frederick

30.7k citations

79 papers · 6.2k indexed · 5 hit papers · h-index 32

Molecular Biology top 2%
Oncology top 0.5%
Immunology top 1%
Cancer Research top 1%
Pulmonary and Respiratory Medicine top 5%

Co-authors: Keith T. Flaherty Jennifer A. Wargo Zachary A. Cooper David E. Fisher Genevieve M. Boland Michal Barzily-Rokni Ravid Straussman Ryan J. Sullivan
Topics: Melanoma and MAPK Pathways (42 papers)Cancer Immunotherapy and Biomarkers (20 papers)Immunotherapy and Immune Responses (17 papers)
Cited by: Oncology Immunology Cancer Research
Journals: Nature Proceedings of the National Academy of Sciences Journal of Clinical Investigation
Partner nations: United States China Switzerland

In The Last Decade

Dennie T. Frederick

71 papers receiving 6.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

2012 1.4k citations Ravid Straussman, Michal Barzily-Rokni et al. profile →
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

2013 610 citations Rizwan Haq, Dennie T. Frederick et al. profile →
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

2018 456 citations Dennie T. Frederick, Benchun Miao et al. profile →
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy

2019 438 citations Dennie T. Frederick, Jennifer A. Lo et al. profile →
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

2014 357 citations David J. Konieczkowski, Cory M. Johannessen et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Dennie T. Frederick

Since Specialization

Citations

This map shows the geographic impact of Dennie T. Frederick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennie T. Frederick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennie T. Frederick more than expected).

Fields of papers citing papers by Dennie T. Frederick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dennie T. Frederick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennie T. Frederick. The network helps show where Dennie T. Frederick may publish in the future.

Co-authorship network of co-authors of Dennie T. Frederick

This figure shows the co-authorship network connecting the top 25 collaborators of Dennie T. Frederick. A scholar is included among the top collaborators of Dennie T. Frederick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dennie T. Frederick. Dennie T. Frederick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of potent biparatopic antibodies targeting FGFR2 fusion–driven cholangiocarcinoma 2025 ·Journal of Clinical Investigation ·(unknown),(unknown),Dennie T. Frederick,(unknown),(unknown),Alessandro Sinopoli,Tianyu Song,Yao He,(unknown),(unknown),Liang Chang,(unknown),(unknown),(unknown),(unknown),Yuen‐Yi Tseng,Nabeel Bardeesy,William R. Sellers	0
2	Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation events 2025 ·Scientific Reports ·Li Chen,Iulian Pruteanu-Malinici,Anahita Dastur,(unknown),Dennie T. Frederick,Ruslan I. Sadreyev,Cyril H. Benes	0
3	Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy 2023 ·Frontiers in Immunology ·(unknown),(unknown),Gege Xu,(unknown),Rachel Rice,Yana G. Najjar,Joseph Markowitz,Lisa M. Ebert,Michael P. Brown,Gonzalo Tapia Rico,Dennie T. Frederick,(unknown),Daniel Serie,Klaus Lindpaintner,Flavio Schwarz,Genevieve M. Boland	9
4	Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma 2022 ·Life Science Alliance ·David Romano,Lucia García-Gutiérrez,(unknown),David J. Duffy,Keith T. Flaherty,Dennie T. Frederick,Walter Kölch,David Matallanas	5
5	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort 2021 ·Journal for ImmunoTherapy of Cancer ·Xue Bai,Michelle Kim,Gyulnara G. Kasumova,Lu Si,Bixia Tang,Chuanliang Cui,Xiaoling Yang,Xiaoting Wei,Justine V. Cohen,Donald P. Lawrence,Christine Freedman,Riley Fadden,Krista M. Rubin,Tatyana Sharova,Dennie T. Frederick,Keith T. Flaherty,Ryan J. Sullivan,Jun Guo,Genevieve M. Boland	8
6	Targeting the cyclin-dependent kinase 5 in metastatic melanoma 2020 ·Proceedings of the National Academy of Sciences ·Samanta Sharma,Tian Zhang,Wojciech Michowski,Vito W. Rebecca,Min Xiao,Roberta Ferretti,Jan M. Suski,Roderick T. Bronson,João A. Paulo,Dennie T. Frederick,Anne Fassl,Genevieve M. Boland,Yan Geng,Jacqueline A. Lees,René H. Medema,Meenhard Herlyn,Steven P. Gygi,Piotr Siciński	17
7	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance 2020 ·Nature Communications ·Julia Boshuizen,David W. Vredevoogd,Oscar Krijgsman,Maarten A. Ligtenberg,(unknown),Beaunelle de Bruijn,Dennie T. Frederick,Juliana C.N. Kenski,Mara Parren,(unknown),Max F. Madu,Elisa A. Rozeman,Ji‐Ying Song,Hugo M. Horlings,Christian U. Blank,Alexander C. J. van Akkooi,Keith T. Flaherty,Genevieve M. Boland,Daniel S. Peeper	66
8	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era 2020 ·Annals of Surgical Oncology ·Richard J. Straker,Yun Song,James Sun,Adrienne B. Shannon,Leah Cohen,(unknown),(unknown),Kate Krause,Siming Li,Dennie T. Frederick,Kristen E. Rhodin,David M. Brizel,Genevieve M. Boland,Georgia M. Beasley,Evan Wuthrick,Vernon K. Sondak,Jonathan S. Zager,Alexander Lin,John N. Lukens,Giorgos C. Karakousis	10
9	Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation 2019 ·Clinical Cancer Research ·Victoria E. Wang,Jenny Y. Xue,Dennie T. Frederick,Yi Cao,Eva Lin,Catherine Wilson,Anatoly Urisman,David P. Carbone,Keith T. Flaherty,René Bernards,Piro Lito,Jeff Settleman,Frank McCormick	37
10	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations 2017 ·Clinical Cancer Research ·Adam A. Friedman,Yun Xia,Lorenzo Trippa,Long P. Le,Vivien Igras,Dennie T. Frederick,Jennifer A. Wargo,Kenneth K. Tanabe,Donald P. Lawrence,Donna Neuberg,Keith T. Flaherty,David E. Fisher	5
11	Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance 2016 ·Cancer Discovery ·Miles A. Miller,Madeleine J. Oudin,Ryan J. Sullivan,Stephanie J. Wang,Aaron S. Meyer,Hyungsoon Im,Dennie T. Frederick,Jenny Tadros,Linda G. Griffith,Hakho Lee,Ralph Weissleder,Keith T. Flaherty,Frank B. Gertler,Douglas A. Lauffenburger	138
12	Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients 2015 ·Journal of the American Academy of Dermatology ·Mark C. Mochel,Marc R. Hammond,Dennie T. Frederick,Maria B. Alora-Palli,Adriano Piris,Keith T. Flaherty,Mai P. Hoang	8
13	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation 2015 ·Cell Reports ·Hyungsoo Kim,Dennie T. Frederick,Mitchell P. Levesque,Zachary A. Cooper,Yongmei Feng,Clemens Krepler,Laurence M. Brill,Yardena Samuels,Nicholas K. Hayward,Ally Perlina,Adriano Piris,Tongwu Zhang,Ruth Halaban,(unknown),Kevin M. Brown,Jennifer A. Wargo,Reinhard Dummer,Keith T. Flaherty,Ze’ev A. Ronai	49
14	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy 2015 ·JNCI Journal of the National Cancer Institute ·Priscilla K. Brastianos,Ganesh M. Shankar,Corey M. Gill,Amaro Taylor‐Weiner,Naema Nayyar,David J. Panka,Ryan J. Sullivan,Dennie T. Frederick,Malak Abedalthagafi,Pamela S. Jones,Ian F. Dunn,Brian V. Nahed,Javier M. Romero,David N. Louis,Gad Getz,Daniel P. Cahill,Sandro Santagata,William T. Curry,Fred G. Barker	178
15	Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade 2014 ·Cancer Immunology Research ·Zachary A. Cooper,Vikram R. Juneja,Peter T. Sage,Dennie T. Frederick,Adriano Piris,Devarati Mitra,Jennifer A. Lo,F. Stephen Hodi,Gordon J. Freeman,Marcus Bosenberg,Martin McMahon,Keith T. Flaherty,David E. Fisher,Arlene H. Sharpe,Jennifer A. Wargo	192
16	EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma 2014 ·Cancer Discovery ·Benchun Miao,Zhenyu Ji,Li Tan,Michael Taylor,Jianming Zhang,Hwan Geun Choi,Dennie T. Frederick,Raj Kumar,Jennifer A. Wargo,Keith T. Flaherty,Nathanael S. Gray,Hensin Tsao	96
17	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma 2014 ·Cancer Research ·Y.N. Vashisht Gopal,Helen Rizos,Guo Chen,Wanleng Deng,Dennie T. Frederick,Zachary A. Cooper,Richard A. Scolyer,Gulietta M. Pupo,Kakajan Komurov,Vasudha Sehgal,Jiexin Zhang,Lalit R. Patel,Cristiano Gonçalves Pereira,Bradley M. Broom,Gordon B. Mills,Prahlad T. Ram,Paul D. Smith,Jennifer A. Wargo,Georgina V. Long,Michael A. Davies	148
18	A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitorsbreakdown → 2014 ·Cancer Discovery ·David J. Konieczkowski,Cory M. Johannessen,Omar O. Abudayyeh,Jong Wook Kim,Zachary A. Cooper,Adriano Piris,Dennie T. Frederick,Michal Barzily-Rokni,Ravid Straussman,Rizwan Haq,David E. Fisher,Jill P. Mesirov,William C. Hahn,Keith T. Flaherty,Jennifer A. Wargo,Pablo Tamayo,Levi A. Garraway	357
19	The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα 2014 ·Cancer Discovery ·Michael P. Smith,Berta Sanchez‐Laorden,Kate O’Brien,Holly Brunton,Jennifer Ferguson,Helen L. Young,Nathalie Dhomen,Keith T. Flaherty,Dennie T. Frederick,Zachary A. Cooper,Jennifer A. Wargo,Richard Marais,Claudia Wellbrock	171
20	Elucidating Distinct Roles for NF1 in Melanomagenesis 2012 ·Cancer Discovery ·Ophélia Maertens,Bryan W. Johnson,Pablo E. Hollstein,Dennie T. Frederick,Zachary A. Cooper,Ludwine Messiaen,Roderick T. Bronson,Martin McMahon,Scott R. Granter,Keith T. Flaherty,Jennifer A. Wargo,Richard Marais,Karen Cichowski	184

About Dennie T. Frederick

Dennie T. Frederick is a scholar working on Oncology, Immunology and Cancer Research, having authored 79 papers that have together received 6.2k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (42 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Immunotherapy and Immune Responses (17 papers). The work is most often cited by research in Oncology (3.2k citations), Immunology (1.7k citations) and Cancer Research (1.1k citations). Dennie T. Frederick has collaborated with scholars based in United States, China and Switzerland. Frequent co-authors include Keith T. Flaherty, Jennifer A. Wargo, Zachary A. Cooper, David E. Fisher, Genevieve M. Boland, Michal Barzily-Rokni, Ravid Straussman, Ryan J. Sullivan, Antoni Ribas and Joshua Gould. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact